West Nile Virus Infections - Pipeline Review, H1 2012

Global Markets Direct, May 2012, Pages: 35

West Nile Virus Infections – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'West Nile Virus Infections - Pipeline Review, H1 2012', provides an overview of the West Nile Virus Infections therapeutic pipeline. This report provides information on the therapeutic development for West Nile Virus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for West Nile Virus Infections. 'West Nile Virus Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for West Nile Virus Infections.
- A review of the West Nile Virus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the West Nile Virus Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of West Nile Virus Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

West Nile Virus Infections Therapeutic Products under Development, Key Players in West Nile Virus Infections Therapeutics, West Nile Virus Infections Pipeline Overview, West Nile Virus Infections Pipeline, West Nile Virus Infections Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
West Nile Virus Infections Overview
Therapeutics Development
An Overview of Pipeline Products for West Nile Virus Infections
West Nile Virus Infections Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
West Nile Virus Infections Therapeutics – Products under Development by Companies
Companies Involved in West Nile Virus Infections Therapeutics Development
CEL-SCI Corporation
Hemispherx Biopharma, Inc.
BioMAS Ltd.
MacroGenics, Inc.
West Nile Virus Infections – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ChimeriVax-West Nile - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alferon N Injection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGAWN1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
West Nile Virus Infections Therapeutics – Drug Profile Updates
West Nile Virus Infections Therapeutics - Dormant Products
West Nile Virus Infections – Product Development Milestones
Featured News & Press Releases
Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for West Nile Virus Infections, H1 2012
Products under Development for West Nile Virus Infections – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
CEL-SCI Corporation, H1 2012
Hemispherx Biopharma, Inc., H1 2012
BioMAS Ltd., H1 2012
MacroGenics, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
West Nile Virus Infections Therapeutics – Drug Profile Updates
West Nile Virus Infections Therapeutics – Dormant Products

List of Figures
Number of Products under Development for West Nile Virus Infections, H1 2012
Products under Development for West Nile Virus Infections – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Rotavirus Infections – Pipeline Review, H1 2013
• Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2012
• Herpes Simplex Infections - Pipeline Review, H1 2013
• Community-Acquired Infections – Pipeline Review, H1 2013
• Human Papillomavirus Infections - Pipeline Review, H1 2013
• Lung Infections – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Influenza A Infections - Pipeline Review, H1 2013